https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/NTRA/natera-esmo-2026-abstracts-ultrasensitive-mrd-technology BiopharmaWatch en 2026-10-18T22:10:00.000Z ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology https://www.biopharmawatch.com/news/ABBV/abbvie-esmo-2026-oncology-data-presentation BiopharmaWatch en 2026-10-18T22:10:00.000Z AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio https://www.biopharmawatch.com/news/INCY/incyte-oncology-data-esmo-congress-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/ZNTL/zentalis-azenosertib-overall-survival-data-esmo-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-abstracts-esmo-congress-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress https://www.biopharmawatch.com/news/MANE/veradermics-conference-call-phase-3-results-hair-loss BiopharmaWatch en 2026-10-18T22:00:00.000Z Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss https://www.biopharmawatch.com/news/IRON/disc-medicine-webcast-apollo-phase-3-results BiopharmaWatch en 2026-10-18T21:00:00.000Z Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-uegw-2026-presentations BiopharmaWatch en 2026-10-18T13:30:00.000Z Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 https://www.biopharmawatch.com/news/ALGN/align-technology-patent-infringement-case-angelalign BiopharmaWatch en 2026-10-17T01:11:00.000Z Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent Court